ASH 2020 | IKEMA update: isatuximab and kD in R/R myeloma
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, discusses the results of an interim analysis of the IKEMA study (NCT03275285): A Phase III trial investigating carfilzomib (K) and dexamethasone (d) with or without isatuximab (isa) in relapsed/refractory (R/R) multiple myeloma. Isatuximab is an anti-CD38 monoclonal antibody with proven efficacy in myeloma. 302 patients with 1-3 prior lines of therapy were randomized to receive Isa-Kd or Kd. The planned interim efficacy analysis found that at a median follow-up of 20.7 months, median progression free survival was prolonged in the Isa-Kd arm compared to the Kd arm, as was the complete remission rate. Overall response rate and measurable residual disease negativity rate were also improved by the addition of Isa. Isa-Kd was well tolerated and its benefit-risk profile is promising, with no additional safety signals seen with its addition to Kd. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
